Wordt geladen...
Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 therapeutic agents, are now approved by the Food and Drug Administration for treatment of various types of cancer. However, the therapeutic efficacy of ICIs varies among patients and cancer types. Moreover, most patients do not...
Bewaard in:
| Gepubliceerd in: | Immune Netw |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
The Korean Association of Immunologists
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7049585/ https://ncbi.nlm.nih.gov/pubmed/32158591 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4110/in.2020.20.e3 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|